Nobel Prize for novel cancer therapies
4 October 2018
Two of the men responsible for the discovery and development of checkpoint inhibitors, therapies that revolutionised the way metastatic melanoma patients are treated, extending lives and improving quality of life for countless patients, were awarded this year’s Nobel Prize in Physiology or Medicine.
Professor James P. Allison from MD Anderson Cancer Centre, and Professor Tasuku Honjo from Kyoto University were jointly awarded the Nobel Prize for their separate work from the early 1990’s, where they each discovered a different protein that plays a major role in regulating the immune system.
The immune system is a balancing act – it is constantly trying to fight off foreign invaders, like viruses and bacteria, without harming the body – that relies heavily on an intricate system of brakes and accelerators. Sometimes the balance is off, resulting in autoimmune diseases where the immune system attacks the body, or diseases like cancer, where the immune system does not recognise that there is anything amiss.
Both Professor Allison and Professor Honjo discovered molecules that act as a brake in the immune system, halting its action and allowing cancers to grow. In Professor Allison’s research, he showed that blocking the molecule he discovered, CTLA-4, could switch off the brake, allowing the immune system to recognise a tumour and attack it. His work lead to the development of the melanoma fighting drug ipilimumab. Professor Honjo discovered the protein PD-1, and found that blocking it allows the immune system to recognise cancer as an invader and mount an immune response. This led to the manufacture of the immunotherapies nivolumab and pembrolizumab.
Ipilimumab, nivolumab and pembrolizumab are now used extensively to treat metastatic melanoma, working to help patient’s own bodies to recognise and fight the disease. Since these treatments have become available, melanoma patients have a better prognosis than ever before.
The two men will receive their Nobel Prizes at a formal ceremony in Stockholm in December. Five different Nobel Prizes are awarded every year, with the Nobel Prize in Physiology or Medicine given to up to three people who have made outstanding discoveries in the fields of medicine or the life sciences. Previous Nobel laureates include three of the men responsible for the discovery of DNA, and the three men who discovered penicillin.
Photograph: Niklas Elmehed/Twitter:NobelPrize
Team Melanoma smashes City2Surf
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Ready to run over melanoma at City2Surf 2019
Lauren O'Brien tells us why she's running for a cause close to her heart
Community Fundraising July Wrap-Up
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
Breast cancer drug may hold key to tackling most deadly type of melanoma
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
MIA takes centre stage at leading cancer conference
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
International Clinical Trials Day 2019
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
Emma Betts' legacy will live on
“I’m the age Emma was when she passed away. It almost feels
Support PBS listing for three adjuvant treatments of resected Stage III melanoma
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
Support PBS listing for pembrolizumab
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.
How are the Premier's Awards helping cancer researchers?
MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.
Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.
Making a difference to many
Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.
Aussie icon Sophie Monk calls on Australians to get behind Melanoma March
Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
Melanoma breakthrough paves way for personalised treatment for all cancer patients
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March announces 2019 Principal Partner
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
Swimming champion Cate Campbell spearheads national campaign to save lives from melanoma
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA experts collaborate on groundbreaking research
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Possible PBS listing for dabrafenib and trametinib
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.
Arden Anglican School wins SunSafe Ambassador competition
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.